TARGOSID ® - Teicoplanin

TARGOSID ® is a Teicoplanin-based drug

THERAPEUTIC GROUP: Antimicrobials - antibiotics for systemic use

Indications TARGOSID ® - Teicoplanin

TARGOSID ® is indicated in the treatment of infections caused by microorganisms sensitive to Glycopeptides and in particular to Teicoplanin.

Great efficacy has been shown in the treatment and prophylaxis of osteomyelitis and endocarditis caused by Staphylococci, Streptococci and Enterococci, also in association with other antibiotics.

Mechanism of action TARGOSID ® - Teicoplanin

Teicoplanin, active ingredient of TARGOSID ®, is a tetracyclic glycopeptide secondary metabolite of Actinoplanes teichomyceticus, characterized by an amino acid structure to which different glucose residues are associated which influence its pharmacokinetic properties.
Administered intravenously or intramuscularly, Teicoplanin is rapidly distributed towards the peripheral districts, easily permeating the bacterial wall of Gram positive microorganisms and exerting on them an impressive bactericidal activity guaranteed by the ability to form a molecular complex with high affinity with the dextro-alanine dimer. terminal of the glycan pentapeptide, thus preventing the transglycosylase and transpeptase function, fundamental in structuring the bacterial wall.
The aforesaid mechanism of action to which the activation of the parietal hydrolases is associated determines a greater fragility of the bacterial wall which determines bacteriolysis by osmotic shock.
Despite the great efficacy of action of these antibiotics, over time a series of changes to the normal bacterial phenotype have been observed which have determined the onset of resistance mechanisms, such as those observed for E.faecalis and E.faecium, capable of completely nullify the bactericidal activity of both Teicoplanin and other glycopeptides such as Vancomycin.
Once the biological activity, present also in the serous cavities but not in the cerebrospinal fluid, Teicoplanin is eliminated mainly unchanged, following glomerular filtration, through the urine.

Studies carried out and clinical efficacy

THEICOPLANINE ANTIVIRAL CAPACITY

J Antimicrob Chemother. 2012 Oct; 67: 2537-8.

Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C.

Maieron A, Kerschner H.

Study that demonstrates the efficacy of a semi-synthetic antibiotic such as Teicoplanin to inhibit viral replication, thus reducing the viral load in patients with Hepatitis C.

GREATER SENSITIVITY "OF STAFILOCOCCUS AUREUS TO TEICOPLANINA

J Chemother. 2012 Aug; 24: 187-90.

Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.

Tascini C, Flammini S, Leonildi A, Ciullo I, Tagliaferri E, Menichetti F.

Italian study that demonstrates the greater presence of Staphylococcus aureus strains resistant to Vancomycin rather than Teicoplanin. These evidences are fundamental in order to correctly adapt the antibiotic therapy, avoiding the onset of further resistance and thus maintaining a good therapeutic efficacy.

THEICOPLANINA AND ATRIAL BLOCK

J Clin Pharm Ther. 2012 Dec 28.

Complete heart block in a patient with acute lymphoblastic leukemia: teicoplanin as a possible cause and review of literature.

Sharif-Yakan A, Arabi M, Musharrafieh UM, Bitar FF, Saab R, Abboud MR, Muwakkit S.

Study that reports the onset of atrioventricular block in a patient suffering from acute lymphoblastic leukemia and simultaneously undergoing therapy with Teicoplanin.
These case reports emphasize the importance of ongoing medical supervision of drug therapies such as Teicoplanin-based.

Method of use and dosage

TARGOSID ®
Powder and solvent for solution for injection for intramuscular and intravenous use of 200 - 400 mg of Teicoplanin.
Given the specialist use of this antibiotic, both dosage and administration should be defined and supervised by medical personnel, who in addition to formulating the optimal dosage according to the patient's clinical condition should also choose the best possible route of administration.

Warnings TARGOSID ® - Teicoplanin

The use of TARGOSID ® must necessarily be supervised by medical personnel, in order to optimize the therapeutic efficacy and at the same time control the potential side effects.
In fact, it is advisable to correct the dosages in patients suffering from kidney diseases or undergoing other contextual antibiotic treatments.
Prolonged use over time could determine the appearance of resistance mechanisms, responsible for bacterial superinfections and the consequent worsening of the clinical picture, with the appearance of auditory, hematological, hepatic and renal toxicity.
It is recommended to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the absence of clinical trials able to fully characterize the safety profile of the antibiotic for fetal health and for the infant, it is recommended to avoid the use of TARGOSID ® during pregnancy and in the subsequent breastfeeding period. .

Interactions

In order to minimize the potential side effects of Teicoplanin, it would be advisable to avoid the simultaneous intake of drugs or active ingredients with ototoxic, nephrotoxic, hepatotoxic and cardiotoxic potential.

Contraindications TARGOSID ® - Teicoplanin

The use of TARGOSID ® is contraindicated in patients hypersensitive to the active substance or to one of its excipients as well as in patients with severe renal insufficiency.

Undesirable Effects - Side Effects

Although therapy with TARGOSID ® is generally well tolerated, different studies and numerous evidences from common outpatient practice have reported the onset of pain at the injection site, hypersensitivity reactions with skin rashes and itching, alterations of the haematological picture and rarely gastrointestinal disorders. intestinal and hepato-renal.

Note

TARGOSID ® is a prescription drug.

The information on TARGOSID ® - Teicoplanin published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.